Does Sientra, Inc. (SIEN) Have Any Gas After Today’s Significant Increase?

February 15, 2018 - By Clifton Ray

Investors sentiment decreased to 1.52 in Q3 2017. Its down 0.34, from 1.86 in 2017Q2. It is negative, as 9 investors sold Sientra, Inc. shares while 14 reduced holdings. 13 funds opened positions while 22 raised stakes. 14.36 million shares or 1.78% more from 14.11 million shares in 2017Q2 were reported.
Schwab Charles Invest reported 0% in Sientra, Inc. (NASDAQ:SIEN). 1,000 are owned by Financial Bank Of Montreal Can. 2.73M are owned by Clarus Ventures Limited Liability Com. Pura Vida Invests Ltd Liability invested in 1.45% or 187,800 shares. Morgan Stanley holds 0% or 138,532 shares. Strs Ohio holds 3,800 shares or 0% of its portfolio. Bridgeway Mngmt Incorporated invested 0.05% in Sientra, Inc. (NASDAQ:SIEN). Lord Abbett Ltd, a New Jersey-based fund reported 354,080 shares. Hightower Advsr Ltd Company holds 0% or 19,595 shares in its portfolio. California State Teachers Retirement Sys reported 22,536 shares or 0% of all its holdings. Schroder Inv Gru holds 0.01% of its portfolio in Sientra, Inc. (NASDAQ:SIEN) for 437,276 shares. Ameriprise Fincl owns 329,741 shares. Rhumbline Advisers invested in 16,564 shares or 0% of the stock. State Board Of Administration Of Florida Retirement System reported 15,566 shares. Barclays Public Limited invested in 10,132 shares or 0% of the stock.

The stock of Sientra, Inc. (NASDAQ:SIEN) is a huge mover today! The stock increased 3.59% or $0.39 during the last trading session, reaching $11.24. About 127,260 shares traded. Sientra, Inc. (NASDAQ:SIEN) has risen 27.61% since February 15, 2017 and is uptrending. It has outperformed by 10.91% the S&P500.
The move comes after 5 months positive chart setup for the $218.08 million company. It was reported on Feb, 15 by Barchart.com. We have $12.25 PT which if reached, will make NASDAQ:SIEN worth $19.63 million more.

Analysts await Sientra, Inc. (NASDAQ:SIEN) to report earnings on March, 13. They expect $-0.68 EPS, down 58.14 % or $0.25 from last year’s $-0.43 per share. After $-0.74 actual EPS reported by Sientra, Inc. for the previous quarter, Wall Street now forecasts -8.11 % EPS growth.

Sientra, Inc. (NASDAQ:SIEN) Ratings Coverage

Among 5 analysts covering Sientra (NASDAQ:SIEN), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Sientra had 12 analyst reports since August 14, 2015 according to SRatingsIntel. As per Tuesday, September 26, the company rating was maintained by Stifel Nicolaus. Stifel Nicolaus maintained it with “Hold” rating and $1100 target in Wednesday, August 9 report. As per Thursday, January 4, the company rating was maintained by Canaccord Genuity. The stock of Sientra, Inc. (NASDAQ:SIEN) earned “Buy” rating by Canaccord Genuity on Sunday, October 8. Canaccord Genuity maintained it with “Buy” rating and $18 target in Tuesday, October 17 report. As per Friday, January 19, the company rating was upgraded by Stifel Nicolaus. On Monday, August 28 the stock rating was initiated by Canaccord Genuity with “Buy”. As per Thursday, February 11, the company rating was reinitiated by Stifel Nicolaus. The rating was upgraded by William Blair on Wednesday, September 13 to “Outperform”. The rating was reinitiated by William Blair with “Market Perform” on Wednesday, August 10.

More recent Sientra, Inc. (NASDAQ:SIEN) news were published by: Globenewswire.com which released: “Sientra® Provides Update on FDA Review of US Manufacturing Facility” on January 30, 2018. Also Globenewswire.com published the news titled: “Lubrizol Customer, Sientra, Inc., Receives FDA Approval to Manufacture Breast …” on February 06, 2018. Globenewswire.com‘s news article titled: “Sientra Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)” with publication date: January 25, 2018 was also an interesting one.

Sientra, Inc., a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. The company has market cap of $218.08 million. The firm offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; and breast tissue expanders. It currently has negative earnings. It also provides body contouring products; facial and nasal implants; scar management products under the bioCorneum and Silishield brand names; saline-filled breast implant sizers to identify the correct style and size of implants; and non-breast tissue expanders for expanding tissue and skin surface area for burn care and other reconstructive use.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.